MedPath

Hangzhou Sumgen Biotech Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:2
Completed:0

Trial Phases

2 Phases

Phase 1:6
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (85.7%)
Phase 3
1 (14.3%)

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Phase 3
Recruiting
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Drug: SG301 Injection
Drug: SG301 placebo
First Posted Date
2024-07-19
Last Posted Date
2025-06-27
Lead Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Target Recruit Count
360
Registration Number
NCT06508983
Locations
🇨🇳

Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China

🇨🇳

Guangzhou First People's Hospital, Guangzhou, Guangdong, China

🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 9 locations

SG2918 For Advanced Malignant Tumors

Phase 1
Recruiting
Conditions
Advanced Malignant Tumors
Interventions
First Posted Date
2023-12-12
Last Posted Date
2025-06-26
Lead Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Target Recruit Count
117
Registration Number
NCT06167486
Locations
🇨🇳

Chongqing University Cancer Hospital, Chongqing, Chongqing, China

🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

and more 3 locations

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Phase 1
Recruiting
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Drug: SG301 SC Injection
Drug: SG301 SC Placebo
First Posted Date
2023-11-22
Last Posted Date
2025-06-25
Lead Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Target Recruit Count
48
Registration Number
NCT06144710
Locations
🇨🇳

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

🇨🇳

The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

🇨🇳

First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

and more 7 locations

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2023-10-10
Last Posted Date
2025-06-27
Lead Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Target Recruit Count
122
Registration Number
NCT06076291
Locations
🇨🇳

The Affiliated Hospital of USTC, Hefei, Anhui, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Henan Cancer Hospital, Zhenzhou, Henan, China

and more 3 locations

SG1906 for CLDN18.2-Positive Solid Tumors

Phase 1
Recruiting
Conditions
Locally Advanced Unresectable or Metastatic Solid Tumors
Interventions
First Posted Date
2023-05-12
Last Posted Date
2025-06-25
Lead Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Target Recruit Count
60
Registration Number
NCT05857332
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

🇨🇳

The First Affiliated Hospital Of Xiamen University, Xiamen, Fujian, China

🇨🇳

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

and more 6 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.